This study will investigate the effects of a novel anticancer agent in subjects with newly diagnosed malignant gliomas, a group of tumors which remains refractory to standard treatment approaches. The study drug inhibits microtubule formation thus disrupting tubulin polymerization. The phase I portion of the study will determine the maximum tolerated dose of the drug, and the phase II portion will determine the response rate.
Showing the most recent 10 out of 600 publications